Track market-moving stories before they get noisy

Accelerating Oasis Beverage Momentum, a Full Quarter of Bluebird Botanical Contribution, and Advancing Federal Hemp Legislation Strengthen the Company's Positioning for Competing under Pending Federal Regulations

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its hemp-derived THC beverage brand Oasis and functional-mushroom brand ATRx Labs, today announced financial results for the third quarter of fiscal year 2026, ended June 30, 2026.

The Company delivered 20% year-over-year revenue growth, driven by a 61% increase in wholesale net sales, increased distribution of its Oasis beverage brand, and the first full quarter of contribution from the recently acquired Bluebird Botanicals.

"The third quarter was another quarter of top-line growth and real strategic progress," said Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD. "Revenue was up 20% year-over-year, our Oasis beverage brand sales continued to grow, and Bluebird Botanicals contributed a full quarter of revenue for the first time. We were not satisfied with our bottom line this quarter but the shortfall was largely the result of deliberate choices. We absorbed one-time costs tied to M&A due diligence and other one-time legal costs, continued to invest in product development, and did the work required to resolve supply-chain and address state-level compliance issues. During July we implemented cost reduction initiatives that we expect to result in saving potential up to $150,000 per month, as we are running the business to be leaner, more flexible, and well positioned to succeed in the market following the effectiveness of pending federal regulation."

"The regulatory picture is also moving in a more constructive direction," Kennedy continued. "A Senate-driven extension has given cbdMD and the broader industry additional time ahead of the November effective date of the H.R. 5371 Sec. 781 legislation to ensure company compliance with the pending laws, and the number of bipartisan legislative proposals continues to grow, including the Beverage Regulatory Parity Act introduced this week, which would regulate hemp-derived beverages much like alcohol. We believe momentum is building toward a workable federal framework, and that well-capitalized, compliance-focused operators with proven quality, safety data, and clinical credibility, such as cbdMD, will be the ones that benefit as clarity emerges."

Highlights for the Third Quarter of Fiscal 2026 and Notable Business Updates

Revenue growth accelerated year-over-year. Net sales increased 20% to $5.6 million in the third quarter of fiscal 2026 from $4.6 million in the prior-year quarter, with wholesale net sales up 61% year-over-year. For the first nine months of fiscal 2026, net sales rose 12% to $16.2 million from $14.5 million in the prior-year period.
Oasis momentum continued to build. The Company added distribution for Oasis in South Carolina and transitioned to a new distribution partner in Texas that more than quadrupled the number of stores with access to the brand, with continued market growth into the fourth quarter. The recently launched Oasis Mixer has been well received and is contributing to brand growth.  Distributor depletions grew 25% in the third fiscal quarter.  We had record distributor depletions in July up over 34% from the Q3 average and currently at a pace to double in August
Oasis ingredient expansion.  As of today, the Company is introducing a zero-proof Kava beverage under its Oasis brand as a follow-on to the successful Oasis Mixer.  Kava is a natural euphoric people can feel! Immediate, functional, and free of intoxication and regulatory overhang of THC. This is the first of other natural compounds we anticipate launching before the end of the calendar year.
Bluebird Botanicals delivered its first full quarter of revenue. Bluebird Botanicals ("Bluebird") contributed more than $0.5 million revenue in the third quarter of fiscal 2026. After creating an earnings drag during integration in the initial quarter, we expect Bluebird to contribute to both revenue and earnings in the fourth fiscal quarter.
A federal extension creates procedural time to advance a permanent fix on Section 781. While the additional time helps cbdMD and the broader industry manage near-term compliance, its more important benefit is the procedural runway it creates for Congress to put a durable, industry-wide framework in place. A Senate stopgap appropriations proposal released in early August 2026 would, through December 11, 2026, temporarily exempt naturally occurring cannabinoids from the revised total-THC definition and the 0.4 milligram per-container limit under Section 781 of H.R. 5371, signed into law in November 2025, providing additional time ahead of the November 12, 2026 effective date both to bring products into compliance and, more significantly, to advance a permanent legislative solution for the industry. The continuing resolution, H.R. 6500, now moves to the House of Representatives for a vote by the end of September.
Bipartisan legislative momentum is growing. A growing number of bipartisan bills would repeal, delay, modify, or replace Section 781's restrictions, including the White House-supported Lawful Hemp Protection Act (H.R. 9830) introduced in July 2026. Most recently, on August 10, 2026, Representatives Beth Van Duyne (R-TX) and Greg Landsman (D-OH) introduced the bipartisan Beverage Regulatory Parity Act, which would establish an alcohol-style regulatory framework for hemp-derived beverages, a development directly relevant to the Company's Oasis brand.
Deliberate investments and one-time costs affected the bottom line. Results reflected more than $100,000 in legal and due-diligence expenses on additional M&A opportunities, continued investment in product development and clinical/regulatory initiatives, including our recent self-GRAS at 200mg per day, and incremental supply-chain and state-level compliance costs, including higher inventory reserves. The Company also identified additional supply-chain savings and, beginning in the fourth quarter of fiscal 2026, implemented cost-reduction initiatives targeting $100,000 to $150,000 in monthly savings (approximately $1.2 million to $1.8 million annualized) expected to improve future financial results and position the Company for a post-regulation market.

Financial Highlights from the Third Quarter of Fiscal Year 2026

Net sales totaled $5.6 million in the third quarter of fiscal 2026, an increase of 20% compared to $4.6 million in the third quarter of fiscal 2025. For the nine months ended June 30, 2026, net sales were $16.2 million, an increase of 12% compared to $14.5 million in the prior-year period.
Direct-to-consumer (e-commerce) net sales were $3.9 million, or 70% of total net sales, an increase of approximately 9% from the third quarter of fiscal 2025. The increase was attributed to addition of Bluebird, with some offsets related to increased state level restrictions.
Wholesale net sales were $1.7 million, or 30% of total net sales, an increase of 61% from the third quarter of fiscal 2025, reflecting continued progress with the Oasis brand and core cbdMD initiatives.
Gross profit as a percentage of net sales was 54.7% in the third quarter of fiscal 2026, compared to 61.5% in the prior-year quarter, primarily reflecting a shift in sales mix toward wholesale, incremental warehouse and repacking costs related to changing state-level requirements, and an increase in inventory reserves in anticipation of pending regulatory changes.
Loss from operations was approximately $1.13 million in the third quarter of fiscal 2026, compared to a loss of approximately $0.90 million in the prior-year period, reflecting the one-time and investment items described above.
Non-GAAP Adjusted EBITDA loss was approximately $508,000 in the third quarter of fiscal 2026, an improvement from an Adjusted EBITDA loss of approximately $624,000 in the third quarter of fiscal 2025.
Net loss attributable to common shareholders for the third quarter of fiscal 2026 was approximately $1.2 million, or $0.11 per share, compared to a net loss of approximately $1.2 million, or $0.21 per share, in the prior-year quarter. For the nine months ended June 30, 2026, net loss attributable to common shareholders improved to approximately $2.4 million, or $0.24 per share, from approximately $3.7 million, or $1.56 per share, in the prior-year period.
At June 30, 2026, the Company had working capital of approximately $4.7 million and cash on hand of approximately $2.1 million, compared to working capital of approximately $3.4 million and cash on hand of approximately $2.3 million at September 30, 2025.

Conference Call Details

The Company will host a conference call at 4:20 pm Eastern Time, on August 13, 2026, to discuss its third quarter fiscal 2026 financial results and business progress.

USA/Canada Dial-in: 888-880-3330
Webcast / Webcast Replay link: https://app.webinar.net/PGD52PJopeq

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands, with a comprehensive line of U.S.-produced THC-free1 CBD products and an array of Farm Bill-compliant Delta 9 products. The Company owns and operates the cbdMD, Paw CBD, and Bluebird Botanicals CBD brands, the Oasis line of hemp-derived THC beverages, the Kavari line of Kava products, and the ATRx Labs functional-mushroom brand. To learn more about cbdMD and its other brands, please visit www.cbdmd.com, www.pawcbd.com, www.ATRxLabs.com, www.bluebirdbotanicals.com, or www.herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.

1 THC-free is defined as below the level of detection using validated scientific analytical methods.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," "proposes," "will," "could," "would," "potential," "continue," "seek," and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: our ability to continue as a going concern; our expectations regarding revenue growth and the performance of our core business and Oasis brand; our ability to drive improved operating results and move closer to sustainable profitability; the expected benefits, synergies, and integration of the Bluebird Botanicals acquisition and our pursuit of additional acquisitions; the anticipated benefits of our cost-reduction and supply-chain initiatives; our expectations regarding federal and state regulatory developments, including proposed legislation and the effective date of Section 781 of the Act, and their impact on our business; and our liquidity and working capital position. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: our ability to continue as a going concern and maintain adequate liquidity; our ability to increase revenues and achieve profitability; our ability to successfully integrate Bluebird Botanicals and realize anticipated synergies and benefits; changes in consumer demand for CBD and hemp-derived products; our ability to maintain compliance with NYSE American continued listing requirements; changes in federal and state laws and regulations governing hemp, CBD, and cannabis products, including the potential impact of Section 781 of the Act and related legislation; our ability to compete effectively in a highly competitive market; our ability to maintain and expand our distribution channels; our ability to develop and successfully launch new products; disruptions in our supply chain or manufacturing operations; our ability to protect our intellectual property; cybersecurity risks and data privacy concerns; our ability to attract and retain key personnel; general economic conditions and their impact on consumer spending; and other risks and uncertainties described under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and our other filings with the Securities and Exchange Commission (the "SEC"). All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statements except as required by applicable law. The information which appears on our websites and our social media platforms is not part of this press release.

cbdMD, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

JUNE 30, 2026 AND SEPTEMBER 30, 2025

(unaudited)

June 30,

September
30,

2026

2025

Assets

Cash and cash equivalents

$         21,18,339

$       22,61,242

Accounts receivable, net

17,52,661

10,40,887

Inventory, net

32,78,436

27,32,127

Inventory prepaid

1,86,763

2,14,795

Prepaid sponsorship

21,161

25,231

Prepaid expenses and other current assets

3,39,162

2,77,147

Total current assets

76,96,522

65,51,429

Other assets:

Property and equipment, net

3,34,840

2,77,377

Operating lease assets

21,83,117

7,03,934

Deposits for facilities

62,708

62,708

Intangible assets, net

19,78,646

21,24,502

Goodwill

1,90,000

-

Investment in other securities, noncurrent

7,00,000

7,00,000

Total other assets

54,49,311

38,68,521

Total assets

$      1,31,45,833

$    1,04,19,950

CONSOLIDATED BALANCE SHEETS

JUNE 30, 2026 AND SEPTEMBER 30, 2025

(continued)

June 30,

September 30,

2026

2025

Liabilities and shareholders' equity

Current liabilities:

Accounts payable

$         14,92,250

$       11,73,642

Accrued expenses

5,87,767

7,35,672

Operating leases - current portion

3,50,949

7,78,240

Note payable

7,321

-

Total current liabilities

30,79,569

31,93,843

Long term liabilities:

Operating leases - long term portion

15,83,994

-

Total long term liabilities:

15,83,994

-

Total liabilities:

46,63,563

31,93,843

Commitments and Contingencies

cbdMD, Inc. shareholders' equity:

Preferred stock, authorized 50,000,000 shares, $0.001

par value, 1,591,210 and 1,700,000 shares issued and outstanding,
respectively

1,591

1,700

Common stock, authorized 150,000,000 shares, $0.001

par value, 11,118,820 and 8,917,054  shares issued and outstanding,
respectively

11,119

8,917

Additional paid in capital

19,00,34,330

18,66,50,640

Accumulated deficit

(18,18,34,770)

(17,94,35,150)

Total cbdMD, Inc. shareholders' equity

82,12,270

72,26,107

Total liabilities and shareholders' equity

$      1,28,75,833

$    1,04,19,950

cbdMD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025

(unaudited)

Three months ended June 30,

Nine months ended June 30,

2026

2025

2026

2025

Gross Sales

$         55,53,738

$       46,06,796

$ 1,62,10,701

$ 1,44,69,698

Total Net Sales

$         55,53,738

$       46,06,796

$ 1,62,10,701

$ 1,44,69,698

Cost of sales

$         25,16,204

$       17,75,709

$    69,14,955

$    52,78,638

Gross Profit

$         30,37,534

$       28,31,087

$    92,95,746

$    91,91,060

Operating expenses

$         41,68,011

$       37,35,773

$ 1,15,13,299

$ 1,06,67,834

Loss from operations

$        (11,30,477)

$        (9,04,686)

$   (22,17,553)

$   (14,76,774)

Decrease (increase) in fair value of convertible debt

$                        -

$                      -

$                   -

$         87,380

Interest expense (income)

$                3,275

$              9,414

$           9,238

$         28,460

Loss before provision for income taxes

$        (11,27,202)

$        (8,95,272)

$   (22,08,315)

$   (13,60,934)

Net (loss) income

$        (11,27,202)

$       (8,95,272)

$   (22,08,315)

$   (13,60,934)

Preferred dividends

$              71,031

$         3,33,500

$      1,91,307

$    23,34,501

Net Loss attributable to cbdMD, Inc. common
shareholders

$        (11,98,233)

$     (12,28,772)

$   (23,99,622)

$   (36,95,435)

Net Loss per share:

Basic and diluted earnings per share

$                 (0.11)

$              (0.21)

$          (0.24)

$          (1.56)

Weighted average number of shares Basic and Diluted:

1,06,16,617

57,83,354

1,00,16,121

23,76,157

cbdMD, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE NINE MONTHS ENDED JUNE, 2026 AND 2025

(unaudited)

June 30,

June 30,

2026

2025

Cash flows from operating activities:

Net Loss

$     (22,08,315)

$        (13,60,934)

Adjustments to reconcile net loss to net

cash used by operating activities:

Restricted stock expense

$        3,62,109

$                3,693

Issuance of stock for services

$                     -

$              82,250

Intangibles amortization

$        6,12,751

$           5,73,801

Depreciation

$        1,43,210

$           2,90,275

Decrease in fair value of convertible debt

$                     -

$             (87,380)

Amortization of operating lease asset

$        5,24,525

$           4,99,309

Changes in operating assets and liabilities:

Accounts receivable

$       (6,90,727)

$              17,351

Inventory

$       (2,83,110)

$          (4,33,495)

Prepaid inventory

$           28,032

$          (2,21,034)

Prepaid expenses and other current assets

$           49,023

$              37,017

Accounts payable and accrued expenses

$           77,762

$          (1,94,632)

Operating lease liability

$       (5,77,005)

$          (4,23,855)

Deferred revenue / customer deposits

$          (15,377)

$                6,008

Cash flows from operating activities

$     (19,77,122)

$        (12,11,626)

Cash flows from investing activities:

Purchase of property and equipment

$       (1,88,615)

$          (1,81,368)

Purchase of Bluebird

$           56,427

$                        -

Cash flows from investing activities

$       (1,32,188)

$          (1,81,368)

Cash flows from financing activities:

Proceeds from ELOC draw

$           61,990

Proceeds from issuance of preferred stock

$      20,24,693

Preferred dividends distribution

$       (1,20,276)

$                        -

Cash flows from financing activities

$      19,66,407

$                        -

Net increase (decrease) in cash

$       (1,42,903)

$        (13,92,994)

Cash and cash equivalents, beginning of period

$      22,61,242

$         24,52,553

Cash and cash equivalents, end of period

$      21,18,339

$         10,59,559

Supplemental Disclosures of Cash Flow Information:

2026

2025

Cash Payments for:

Interest expense

$              19,046

Non-cash financing/investing activities:

Issuance of shares for conversion of debt and accrued interest

$                     -

$         10,79,639

Change in lease asset related to extinguishment of HQ lease and new warehouse lease

$                     -

$        (17,23,544)

ROU Assets obtained in exchange for lease liabilities

$      20,03,708

$                        -

All stock purchase of Bluebird

$        9,36,992

$                        -

Conversion of accrued preferred dividends to preferred stock

$                     -

$         66,72,652

Preferred dividends accrued but not paid

$           71,031

$         23,34,501

Non-GAAP Financial Measures

This press release includes a financial measure, Adjusted EBITDA, that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. defines Adjusted EBITDA as GAAP loss from operations adjusted to (i) depreciation and amortization, (ii) stock-based compensation expense, (iii) inventory reserve, (iii) regulatory and legal matters, and (iv) mergers and acquisitions and financing transaction expenses for the periods presented. cbdMD, Inc. has included Adjusted EBITDA because management uses this measure to assess operating performance and to highlight trends in the business that may not otherwise be apparent when relying on GAAP measures. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, loss from operations as an indicator of operating performance and, as presented, may not be comparable to similarly titled measures reported by other companies. A reconciliation to the most directly comparable GAAP measure is provided below.

Reconciliation of GAAP Loss from Operations to Non-GAAP Adjusted EBITDA (Unaudited)

cbdMD, Inc.

NON GAAP ADJUSTED EBITDA

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025

(unaudited)

Three months ended June 30,

Nine months ended June 30,

2026

2025

2026

2025

GAAP (loss) from operations

$     (11,30,477)

$          (9,04,686)

$     (22,17,553)

$   (5,72,088)

Adjustments:

Depreciation and Amortization (1)

$         2,58,969

$           2,80,172

$         7,55,962

$    5,83,903

Employee and director stock compensation (2)

$            65,159

$                   825

$         3,66,963

$         5,016

Inventory Reserve (3)

$         1,20,000

$         1,20,000

Regulatory and Legal Mattters (4)

$            53,000

$            53,000

Mergers and Acquisitions and financing transaction expense (5)

$         1,26,000

$                        -

$         1,57,671

$                 -

Non-GAAP adjusted EBITDA

$        (5,07,349)

$          (6,23,689)

$       (7,63,957)

$       16,831

(1) Represents depreciation of property, plant and equipment and amortization of the Company's intangible assets.

(2) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period.

(3) Represents additional inventory reserve in preparation for pending regulatory changes.

(4) Represents regulatory costs associated with pending legislation.

(5) Represents costs associated with the Bluebird acquisition, preferred stock offerings and review of additional potential acquisition opportunities.

Contacts

Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

Company backs the Barr-Craig framework and the administration's call to fix the federal hemp definition before the November deadline

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leader in hemp-derived wellness, today announced its support for the bipartisan Lawful Hemp Protection Act, introduced July 21 by Rep. Andy Barr (R-KY) and Rep. Angie Craig (D-MN). The legislation would establish a long-term federal regulatory framework for hemp-derived products while preserving consumer access to lawful products. The Company also expressed support for the Administration's call to address the federal hemp definition through pending budget legislation.

The legislation comes at a pivotal time for the U.S. hemp industry. Under Section 781 of the Fiscal Year 2026 appropriations law, the federal definition of hemp is scheduled to narrow on November 12, 2026. Without congressional action, many lawful full-spectrum CBD and hemp wellness products could be removed from the marketplace. The Lawful Hemp Protection Act would repeal that provision and replace it with a durable, science-based framework.

The bipartisan sponsorship reflects a growing consensus that responsible regulation, rather than prohibition, is the appropriate path forward for the hemp industry. The bill would establish FDA oversight for hemp-derived products, with mandatory third-party testing, transparent labeling, a 21-and-over age requirement, and domestic sourcing, while targeting the synthetic intoxicants that have drawn scrutiny to the category.

Specifically, cbdMD supports a federal framework that:

Protects access to responsibly manufactured full-spectrum CBD Requires independent testing and accurate labeling Establishes clear manufacturing and marketing standards, including limits on youth-focused marketing Prevents youth access through a 21-and-over requirement Restricts synthetic and artificially modified cannabinoids Preserves lawful interstate commerce for compliant products cbdMD also welcomed the Office of Management and Budget's recent call for Congress to update the hemp definition through the funding process, which the company believes could provide relief before the November deadline if enacted.

As one of the nation's longest-standing hemp-derived CBD companies, cbdMD believes a consistent federal regulatory framework would significantly benefit consumers and responsible businesses alike by improving consumer confidence, strengthening safety standards, and providing greater certainty for manufacturers and retailers.

"Reps. Barr and Craig have demonstrated bipartisan leadership by advancing a practical regulatory framework for hemp-derived products," said Ronan Kennedy, Chief Executive Officer of cbdMD. "Responsible companies have long supported clear federal standards that protect consumers, promote product quality, and distinguish compliant hemp products from illicit synthetic intoxicants. We encourage Congress to act before the November implementation deadline."

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a Charlotte, North Carolina-based hemp-derived wellness company committed to safe, high-quality, science-backed products. Its family of brands includes cbdMD, cbdMD Science, Bluebird Botanicals, Paw CBD, Oasis, and ATRx Labs. For more information, visit cbdMD.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Statements regarding pending legislation, regulatory developments, and their potential impact on the company are based on current expectations and are subject to risks and uncertainties, including the outcome of the legislative and regulatory processes described above and risks disclosed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Actual results may differ materially. The company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

As federal reclassification efforts advance and major U.S. exchanges open to compliant operators, cbdMD points to its position as an established, NYSE American–listed company in a maturing cannabinoid category

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today welcomed the Administration's call urging Congress to ensure the fair treatment of hemp-derived products under federal law and requesting immediate action to revise federal hemp regulation to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority the Administration strongly supports. The request calls on Congress to ensure fair treatment of hemp-derived products by preserving access to appropriate full-spectrum CBD products, while preserving Congress's intent to restrict products that pose health risks. The Administration also urged Congress to adopt a responsible federal framework or, at minimum, extend the current implementation timeline so that lawmakers have time to get the policy right. The request builds on the President's earlier public statements urging lawmakers to protect access to the full-spectrum CBD products that millions of Americans rely on.

"We are encouraged to see the Administration advocating so clearly for responsible, science-backed hemp products that consumers depend on every day," said Ronan Kennedy, Chief Executive Officer of cbdMD. "cbdMD has always believed the future of this category is built on quality, transparency, and clear rules that distinguish responsible operators from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty for compliant companies is exactly what this industry and the people it serves deserve. We commend the policymakers who are working toward that outcome."

Separately, broader federal cannabis policy developments continue to draw investment, research, and institutional attention to the cannabinoid category. Notably, major U.S. exchanges have begun permitting the listing of the plan-touching operators that comply with federal, state and local medical cannabis framework. Although cannabis reclassification is distinct from the federal treatment of hemp-derived products, recent exchange-listing developments for compliant cannabis operators reflect a market that is moving toward greater legitimacy, transparency, and regulatory maturity. As an established hemp-derived wellness company with recognized brands, national distribution, and a listing on a national securities exchange, cbdMD believes it is well-positioned as the cannabinoid category moves toward greater maturity, transparency, and regulatory clarity.

"We believe cbdMD is purpose built for this next phase of the market," Kennedy added. "Our focus remains on serving our customers with trusted, efficacious products, supporting responsible regulation, and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment may present."

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a leading wellness company headquartered in Charlotte, North Carolina, with a portfolio of trusted hemp-derived and wellness brands, including cbdMD, Bluebird Botanicals, Paw CBD, ATRx Labs, and the Oasis line of hemp-derived THC beverages. The Company is committed to quality, science, and transparency across its product lines. For more information, visit cbdmd.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding potential changes to the federal regulatory framework for hemp-derived products; the timing or outcome of legislative, administrative, or agency action; the evolution of U.S. capital markets and securities exchange listing practices for the cannabinoid category; and the Company's competitive position and potential opportunities. These statements are based on management's current expectations and are subject to known and unknown risks and uncertainties.

Such risks include, without limitation: that Congress or the Administration may not act, may act on a different timeline, or may adopt adverse regulation or regulation different from what is currently proposed; the potential impact of the statutory changes to the federal definition of hemp scheduled to take effect November 12, 2026; the fact that the ongoing federal cannabis reclassification proceedings concern marijuana, are separate from and do not directly govern the regulation of hemp-derived products, and may not conclude on the timeline or with the outcome the Company anticipates; that securities exchange practices regarding the listing of cannabis-related companies may change or may not develop as expected; and other risks described in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts

cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.